Filing Flows › Biodesix (BDSX) › Q3 2026 › vs Q3 2025
Biodesix (BDSX) Q3 2026 vs Q3 2025 (year over year)
Biodesix's revenue rose $2.3M (+10%) from $21.8M in Q3 2025 to $24.0M in Q3 2026. The biggest changes: Diagnostic Tests +$3.2M (+16%); Development Services −$947K (-49%).
Biodesix, Q3 2026: revenue $24.0M (+10% year over year), operating margin -25.4%, net loss $8.0M, operating cash flow −$7.2M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Diagnostic Tests | $23.1M | $19.8M | $3.2M | +16% |
| Development Services | $986K | $1.9M | −$947K | -49% |
| Revenue | $24.0M | $21.8M | $2.3M | +10% |
| Net loss | $8.0M | $8.7M | −$684K | -8% |
| Costs & expenses | $32.1M | $30.5M | $1.6M | +5% |
| Operating costs | $30.2M | $28.8M | $1.3M | +5% |
| Interest & other, net | $1.9M | $1.7M | $255K | +15% |
| Research & development | $3.0M | $3.0M | $2K | +0.1% |
| SG&A | $22.5M | $21.7M | $785K | +4% |
| Other operating costs | $4.7M | $4.1M | $547K | +13% |
| Operating cash sources | $9.5M | $11.3M | −$1.9M | -17% |
| Depreciation & amortization | $1.4M | $1.4M | −$7K | -0.5% |
| Share-based compensation | $852K | $1.1M | −$201K | -19% |
| Cash used in operations | $7.2M | $8.9M | −$1.7M | -19% |
| Net loss absorbed | $8.0M | $8.7M | −$684K | -8% |
| Working capital & other | $1.4M | $2.6M | −$1.2M | -46% |
Questions
How much did Biodesix's revenue grow year over year in Q3 2026?
Biodesix's revenue rose $2.3M (+10%) from $21.8M in Q3 2025 to $24.0M in Q3 2026.
What drove Biodesix's revenue change in Q3 2026?
Diagnostic Tests +$3.2M (+16%); Development Services −$947K (-49%).